Allegro Ophthalmics
US-based Allegro Ophthalmics uses Integrin Peptide Therapy to treat vascular eye diseases.
US-based Allegro Ophthalmics uses Integrin Peptide Therapy to treat vascular eye diseases.
Founded in San Juan Capistrano, California, Allegro Ophthalmics LLC is dedicated to advancing ocular care through innovative treatments for vascular eye diseases. The company's core mission is to improve patient outcomes by leveraging Integrin Peptide Therapy, specifically targeting conditions like intermediate dry age-related macular degeneration (AMD). Allegro's flagship product, Risuteganib, is designed to address unmet medical needs in ophthalmology, positioning the company at the forefront of ocular pharmaceutical development.
Notable affiliations include a licensing agreement with AffaMed Therapeutics, which has received Phase CTA approval in China for Risuteganib. Allegro has also achieved significant milestones such as receiving FDA Special Protocol Assessment (SPA) agreement for its Phase 2b/3 clinical trial of Risuteganib. These accomplishments underscore Allegro's impact on the global ophthalmic pharmaceutical market, highlighting its potential to revolutionize treatment paradigms for vascular eye diseases.
Companies similar to Allegro Ophthalmics include Macuclear, Vitreoretinal Technologies, Alkeus Pharmaceuticals and Aldeyra Therapeutics.
Allegro Ophthalmics was founded in 2011.
Allegro Ophthalmics' headquarters is located in San Juan Capistrano, CA, US.
Allegro Ophthalmics' most recent funding round was for $10.7M (USD) in July 2017.
As of Jul 24, 2017, Allegro Ophthalmics has disclosed funding of $42.7M (USD). Undisclosed round amounts are excluded.
Allegro Ophthalmics has 11 employees as of Feb 5, 2024.
Aldeyra Therapeutics
